beta-blockers or calcium antagonists in silent ischaemia?
1Department of Medicine, University of Florida College of Medicine, Gainesville.
Insights
Silent myocardial ischemia, or painless heart ischemia, is common in coronary artery disease and predicts poor outcomes. Anti-ischemic therapies can reduce silent episodes and may improve prognosis.
Area of Science:
- Cardiology
- Ischemic Heart Disease
- Preventive Cardiology
Background:
- Silent myocardial ischemia occurs in all forms of coronary artery disease, including in asymptomatic individuals and post-myocardial infarction patients.
- A diurnal pattern exists for silent ischemic episodes, mirroring variations in acute myocardial infarction and sudden cardiac death frequency.
- These patterns suggest shared triggering mechanisms linking transient ischemia to major adverse cardiac events.
Purpose of the Study:
- To highlight the clinical significance of unrecognized or silent myocardial ischemia during daily life.
- To examine the prognostic implications of silent ischemia in patients with coronary artery disease.
- To review the impact of anti-anginal agents on silent ischemic episodes.
Main Methods:
- Review of recent literature on silent myocardial ischemia in daily life.
- Analysis of diurnal variations in ischemic episodes, myocardial infarction, and sudden death.
- Multivariate analysis of risk factors for adverse outcomes in coronary artery disease.
Main Results:
- Silent myocardial ischemia is associated with a 2- to 5-fold increased risk of death and non-fatal myocardial infarction.
- Silent ischemia is a stronger independent predictor of outcome than coronary angiography or exercise test results.
- Anti-anginal agents effectively reduce or prevent daily-life silent ischemia, suggesting symptom-focused therapy may be insufficient.
Conclusions:
- Silent myocardial ischemia is a significant independent predictor of adverse outcomes in coronary artery disease.
- Anti-ischemic treatment, not just symptom control, is crucial for managing silent ischemia.
- Further large-scale clinical trials are needed to confirm the benefits of suppressing painless ischemia.
Abstract:
Unrecognized or silent myocardial ischaemia during daily life has generated considerable recent interest as it occurs in all forms of coronary artery disease, ranging from those who are totally asymptomatic to those who have had a myocardial infarction. A characteristic diurnal cycle of both frequency and duration of these ischaemic episodes occurs and is the same as the diurnal variation observed in frequency of acute myocardial infarction and out-of-hospital sudden death. These findings suggest common underlying triggering mechanisms which may couple transient ischaemia to these morbid events. The presence of daily-life silent ischaemia is associated with a two- to five-fold increase in risk of death and similar increases in risk of non-fatal infarction. Multivariate analysis suggests that silent ischaemia is the best independent predictor of outcome (e.g. death, or myocardial infarction) among a number of factors that include coronary angiography and exercise test results. Anti-anginal agents (e.g. nitrates, beta-blockers, calcium antagonists) also reduce or prevent daily-life silent ischaemia. While anti-anginal treatment can control both symptomatic and silent ischaemic episodes, therapy directed towards symptom control alone may be insufficient to control recurrent silent ischaemia in many individuals. A recent report suggests that suppression of painless ischaemia by anti-ischaemic treatment is associated with a reduced risk of adverse outcome. Additional advances in this area will require the results of large, well-controlled multicentre clinical trials, several of which are currently in progress.(ABSTRACT TRUNCATED AT 250 WORDS)
More Related Videos
10:53Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Angina II: Classification